Kits for treating wounds
AssigneeStemnion, Inc.
InventorsVivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
Life of this patent
Estimating the term…
Abstract
The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
Claims4
A kit for use in a method for healing a wound comprising packaging material, an extraembryonic cell-derived cellular cytokine solution composition comprising physiologic concentrations of VEGF, TGFβ2, Angiogenin, PDGF, TIMP-1 and TIMP-2, wherein the physiologic concentration is ˜5.0-16 ng/mL for VEGF, ˜3.5-4.5 ng/mL for Angiogenin, ˜100-165 pg/mL for PDGF, ˜2.5-2.7 ng/mL for TGFβ2, ˜0.68 μg mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, and instructions for the use of the composition to heal a wound, wherein the wound is selected from the group consisting of a surgical incision of the skin or fascia, an ulcer on the skin or a mucous membrane, and a burn.
A kit for use in a method for healing a wound comprising packaging material, an amnion-derived cellular cytokine solution composition comprising physiologic concentrations of VEGF, TGFβ2, Angiogenin, PDGF, TIMP-1 and TIMP-2, wherein the physiologic concentration is ˜5.0-16 ng/mL for VEGF, ˜3.5-4.5 ng/mL for Angiogenin, ˜100-165 pg/mL for PDGF, ˜2.5-2.7 ng/mL for TGFβ2, ˜0.68 μg mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, and instructions for the use of the composition to heal a wound, wherein the wound is selected from the group consisting of a surgical incision of the skin or fascia, an ulcer on the skin or a mucous membrane, and a burn.
A kit for use in a method for healing a wound comprising packaging material, a physiologic cytokine solution composition comprising a therapeutic component consisting of physiologic concentrations of:
- a) VEGF, TGFβ2, Angiogenin, PDGF, TIMP-1 and TIMP-2;
- and
- b) a carrier, wherein the physiologic concentration is ˜5.0-16 ng/mL for VEGF, ˜3.5-4.5 ng/mL for Angiogenin, ˜100-165 pg/mL for PDGF, ˜2.5-2.7 ng/mL for TGFβ2, ˜0.68 μg mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, wherein the carrier is normal saline, PBS, lactated Ringer's solution or cell culture medium, and instructions for the use of the composition to heal a wound, wherein the wound is selected from the group consisting of a surgical incision of the skin or fascia, an ulcer on the skin or a mucous membrane, and a burn.
Dependencies are inferred from the claim text.